Fractyl Health, Inc. GUTS 深 沪
等待开盘 04-02 09:30:00 美东时间
0.4645
+0.007
+1.46%
华盛通- 最 高0.47
- 今 开0.4676
- 成交量 136.09万股
- 最 低 0.4452
- 昨 收 0.4578
- 总市值 7369.24万
- 52周最高 3.03
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 0.3772
- 委 比 -1.64%
- 总股本 1.59亿
- 历史最高 14.50
- 量 比 0.76
- 振 幅 5.42%
- 历史最低 0.3772
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know
Fractyl Health's shares jumped 20.9% after hours following its Q4 2025 results and new weight-maintenance data from the REMAIN-1 Midpoint Cohort.
03-25 14:56
美股夜盘 | Blaize Holdings, Inc.涨48.65%，Next Technology涨35.00%
Blaize Holdings, Inc.涨48.65%；Next Technology涨35.00%；Braze, Inc. Class A涨19.42%
03-25 09:04
Fractyl Health Q4 EPS $(0.07) Beats $(0.19) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.19) by 63.73 percent. This is a 86.54 percent increase over losses of $(0.52) per share from
03-25 04:11
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Fractyl Health Completes Participant Randomization In REMAIN-1 Pivotal Cohort Evaluating Revita For Weight Maintenance Following GLP-1 Therapy Discontinuation
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data
02-26 20:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
Fractyl Health Announces 6-Month Randomized Results From Ongoing REMAIN-1 Midpoint Cohort, Blinded, Sham-Controlled Study Evaluating Revita For Weight Maintenance Following GLP-1 Drug Discontinuation
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerabilityPatients with
01-29 20:04
